Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11297579 | 0.95 | IKBKB (1.00) | IKBKBCA12CA1CA2CA9 | |
| SCHEMBL2434868 | 0.84 | CDK2 (0.74) | IKBKBCYP1A2CYP3A4GAACYP2C19 | |
| SCHEMBL11297594 | 0.83 | IKBKB (0.78) | IKBKBCA12CA1CA2CA9 | |
| SCHEMBL3522231 | 0.81 | IKBKB (0.86) | IKBKBCA12CA1CA2CA9 | |
| SCHEMBL3517766 | 0.80 | IKBKB (0.77) | IKBKBCA12CA1CA2CA9 | |
| SCHEMBL11296744 | 0.79 | IKBKB (0.73) | IKBKBCYP1A2CYP3A4GAACYP2C19 | |
| SCHEMBL11296777 | 0.78 | IKBKB (0.71) | IKBKBCA12CA1CA2CA9 | |
| SCHEMBL11299366 | 0.78 | IKBKB (0.71) | IKBKBCYP1A2CYP3A4GAACYP2C19 | |
| SCHEMBL11296762 | 0.78 | IKBKB (0.71) | IKBKBCYP1A2CYP3A4GAACYP2C19 | |
| SCHEMBL11299433 | 0.78 | IKBKB (0.71) | IKBKBCYP1A2CYP3A4GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CA12 4839/4885CA1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.